CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
The XXVI World Congress of Neurology (WCN 2023) took place in Montreal, Canada and online between 15-19 October.
Nearly half of people who do not have migraine believe the disorder is easily treatable and over a third think it is due to a person’s own unhealthy behaviour. A range of stigmatising attitudes has been revealed in OVERCOME (US), a population-based web survey carried out amongst nearly 12,000 randomly selected individuals in the USA …
Read more »A post hoc analysis of data from the Phase 3 ADVANCE trial has shown that three to four patients with migraine need to be treated with atogepant for one to achieve ≥50% reduction in monthly migraine days from baseline. In the study of 902 patients with migraine, the number needed to treat (NNT) for one …
Read more »Nearly two thirds of patients with episodic migraine treated with galcanezumab or rimegepant in the CHALLENGE-MIG study achieved ≥50% reduction in monthly migraine headache days (MHD/month) from baseline across three months. Of 580 randomised participants (galcanezumab: 287, rimegepant: 293; mean age: 42 years), 83% were female and 81% Caucasian. Galcanezumab was not superior to rimegepant …
Read more »Blocking the peripheral CGRP pathway may have secondary effects on the central nervous system, conclude researchers who tested the effects of galcanezumab on central sensitisation in patients with migraine. In the prospective, open label, single arm study in 86 patients with migraine, central sensitisation inventory (CSI) score was reduced from 36.0 at baseline to 29.7 …
Read more »Atogepant and rimegepant achieved comparable high responder rates in patients with refractory chronic migraine (CM), according to results of a retrospective chart review in a US neurology practice. Of 26 patients (24 with CM, 2 with episodic migraine) who took atogepant for three months, six (23%) achieved ≥77% reduction in total headache days (THD) for …
Read more »Further data from the UNITE study of fremanezumab treatment in 353 patients with episodic migraine and major depressive disorder (MDD) have demonstrated significant effects on disability scores.1 This follows previous reports of improvements in depression scores and monthly migraine days.2 At 12 weeks follow up, mean 6-item Headache Impact Test (HIT-6) scores had fallen by …
Read more »Bariatric surgery may not only enable patients with obesity to lose weight, it may also reduce their migraines, with an accompanying decrease in serum CGRP. In a study of 60 patients with severe obesity and chronic migraine, followed up for a mean 7.5 ± 2.5 months after bariatric surgery, significant reductions were recorded in migraine …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
